secwatch / observer
8-K filed December 5, 2022, 6:59 PM ET ticker ELUT CIK 0001708527
other material confidence high sentiment neutral materiality 0.70

ELUTIA INC. (ELUT): debt financing — Aziyo Biologics offers 2.35M shares at $4.75, netting ~$9.84M; gets $4M loan

ELUTIA INC.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

ELUTIA INC. incurred term loan of $4 million with SWK Funding LLC, as agent.

Instrument
term loan
Principal
$4 million
Counterparty
SWK Funding LLC, as agent
Event
incurrence
Exact text from the filing
Pursuant to the Amendment Letter, the lenders under the Credit Agreement agreed to fund the additional term loan of $4 million (the “Subsequent Term Loan”),
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

ELUTIA INC. amended Amendment Letter to Credit Agreement dated as of August 10, 2022 with SWK Funding LLC valued at additional term loan of $4 million funded subject to conditions including equity raise condition (effective 2022-11-30).

Action
amendment
Agreement
credit facility
Counterparty
SWK Funding LLC
Value
additional term loan of $4 million funded subject to conditions including equity raise condition
Effective
2022-11-30
Exact text from the filing
On November 30, 2022, the Company entered into an amendment letter (the “Amendment Letter”) to the Credit Agreement, dated as of August 10, 2022, by and among the Company, as the Borrower, and its subsidiaries, the financial institutions party thereto from time to time as lenders, and SWK Funding LLC, as agent (as amended by the letter agreement dated as of October 9, 2022, the letter agreement dated as of November 10, 2022, and the letter agreement dated as of November 21, 2022, the “Credit Agreement”). Pursuant to the Amendment Letter, the lenders under the Credit Agreement agreed to fund the additional term loan of $4 million (the “Subsequent Term Loan”), notwithstanding the fact that the specified operational and financial metrics required to be achieved by the Company for its availability have not been satisfied, so long as (i) the request to fund is made on or prior to December 16, 2022 (such funding date, the “Subsequent Funding Date”), (ii) no material adverse effect, default o
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

ELUTIA INC. entered into Underwriting Agreement with Cantor Fitzgerald & Co. valued at public offering of 2,350,000 shares of Class A common stock at $4.75 per share, net proceeds approxi (effective 2022-12-01).

Action
entry
Agreement
underwriting
Counterparty
Cantor Fitzgerald & Co.
Value
public offering of 2,350,000 shares of Class A common stock at $4.75 per share, net proceeds approxi
Effective
2022-12-01
Exact text from the filing
On December 1, 2022, Aziyo Biologics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co., as underwriter (the “Underwriter”), in connection with the public offering, issuance and sale by the Company of 2,350,000 shares of the Company’s Class A common stock, $0.001 par value per share, at a public offering price of $4.75 per share, less underwriting discounts and commissions, pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-267197) and a related prospectus supplement filed with the Securities and Exchange Commission (the “Offering”).
View on SEC.gov

Browse all debt financings →

ELUTIA INC. filing history →

Source: SEC EDGAR
accession 0001104659-22-124337
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.